Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Grieve

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Pharmacology & Therapeutics|March 26, 2009
Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and diseaseEmma Robinson, David J Grieve
Peptides|February 8, 2018
Biochemical properties and biological actions of obestatin and its relevence in type 2 diabetesBrian D Green, David J Grieve
British Journal of Pharmacology|October 19, 2017
New insights into cardiotoxicity caused by chemotherapeutic agentsDavid J Grieve, Sean M Davidson
Clinical Science (London, England : 1979)|May 6, 2017
Are targeted therapies for diabetic cardiomyopathy on the horizon?Mitchel Tate, David J Grieve, Rebecca H Ritchie
British Journal of Pharmacology|August 18, 2009
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?David J Grieve, Roslyn S Cassidy, Brian D Green
Antioxidants & Redox Signaling|February 20, 2013
Conformational change of mitochondrial complex I increases ROS sensitivity during ischemiaNatalia Gorenkova, Emma Robinson, David J Grieve, et al.
Cells|July 26, 2024
Methanolic Extract of Phoenix Dactylifera Confers Protection against Experimental Diabetic Cardiomyopathy through Modulation of Glucolipid Metabolism and Cardiac RemodelingLaaraib Nawaz, David J Grieve, Humaira Muzaffar, et al.
British Journal of Pharmacology|April 26, 2016
Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetesElaine Cowan, Kerry J Burch, Brian D Green, et al.
Cardiovascular Drugs and Therapy|September 29, 2017
Diabetic Nephropathy: a Tangled Web to UnweaveCorey Magee, David J Grieve, Chris J Watson, et al.
British Journal of Pharmacology|September 19, 2014
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesMitchel Tate, Aaron Chong, Emma Robinson, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Pharmacology & Therapeutics|March 26, 2009
Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and diseaseEmma Robinson, David J Grieve
Peptides|February 8, 2018
Biochemical properties and biological actions of obestatin and its relevence in type 2 diabetesBrian D Green, David J Grieve
British Journal of Pharmacology|October 19, 2017
New insights into cardiotoxicity caused by chemotherapeutic agentsDavid J Grieve, Sean M Davidson
Clinical Science (London, England : 1979)|May 6, 2017
Are targeted therapies for diabetic cardiomyopathy on the horizon?Mitchel Tate, David J Grieve, Rebecca H Ritchie
British Journal of Pharmacology|August 18, 2009
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?David J Grieve, Roslyn S Cassidy, Brian D Green
Antioxidants & Redox Signaling|February 20, 2013
Conformational change of mitochondrial complex I increases ROS sensitivity during ischemiaNatalia Gorenkova, Emma Robinson, David J Grieve, et al.
Cells|July 26, 2024
Methanolic Extract of Phoenix Dactylifera Confers Protection against Experimental Diabetic Cardiomyopathy through Modulation of Glucolipid Metabolism and Cardiac RemodelingLaaraib Nawaz, David J Grieve, Humaira Muzaffar, et al.
British Journal of Pharmacology|April 26, 2016
Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetesElaine Cowan, Kerry J Burch, Brian D Green, et al.
Cardiovascular Drugs and Therapy|September 29, 2017
Diabetic Nephropathy: a Tangled Web to UnweaveCorey Magee, David J Grieve, Chris J Watson, et al.
British Journal of Pharmacology|September 19, 2014
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesMitchel Tate, Aaron Chong, Emma Robinson, et al.
Pageof 7